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Aaron Lerner: Perspectives and Lessons Learned from the 
Melatonin Days
We talk much about translational research, sometimes in 
rather simple ways, even separating it from basic knowledge. 
Aaron Lerner created a perfect blend of basic and clinical 
science during a career that spanned more than 60 years. The 
discovery of melatonin was but one of his many important 
discoveries that impacted dermatology and neuroscience, 
part of his role as the leading contributor to the field of der-
matology of the past half century.
Becoming a scientist
By the time that Aaron Lerner started on the melatonin proj-
ect, he had the prepared mind that is so often key to great 
advances in science. He had, early on, a characteristic zest, 
curiosity, and capacity for creating scientific knowledge. 
While he was interested and able in many areas, Lerner’s 
commitment to science became intense when he started col-
lege. He received a BA cum laude in mathematics and chem-
istry, a medical degree, and a doctorate from the department 
of physiological and physical chemistry, all within seven years 
at the University of Minnesota. His research career began 
when he was a second-year undergraduate with investiga-
tions related to dopa, a critical tyrosine derivative involved in 
pigmentation. Before graduating from medical school, with 
another student and without an adviser, he was involved in 
the isolation of a globulin protein that is now recognized as 
the first isolation of a monoclonal antibody, cryoglobulin.
Through a series of scientific adventures and fortuitous 
interactions with preceptors and peers during a stint in the 
Army, Lerner became increasingly interested in issues of pig-
mentation, such as the processes by which tyrosine was con-
verted to melanin. At Case Western Reserve University, he 
obtained further superb postdoctoral training in biochemistry, 
studying processes involved in pigmentation. By the age of 
30, he had written a paper with his close colleague, Thomas 
Fitzpatrick, on melanin pigmentation for a leading publica-
tion, Physiological Reviews; this paper established them as 
among the world’s leading experts on the topic.
Pigmentation led to Aaron Lerner’s abiding interest in der-
matology and ultimately to a situation at the University of 
Michigan, where he could obtain residency training and also 
conduct research. Among many projects during that early 
phase, one of special import was investigating the pituitary 
factor that might be involved in the darkening of skin seen in 
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patients with Addison’s disease. That project was completed 
in Oregon and included the development of an in vitro assay 
using frog pigment cells. Lerner and his colleagues ultimately 
discovered what they called melanocyte-stimulating hor-
mone (MSH), a peptide of great importance in dermatology, 
which is also a part of pituitary stress systems. That peptide—
one of the first neuropeptides to be characterized—is a major 
secretory product of the intermediate lobe of the pituitary 
and is potentially involved in stress and brain function.
The melatonin project
The melatonin project was a natural outgrowth of what had 
gone before. Lerner came to Yale in 1955 with several of his 
colleagues. Waiting for their laboratory to be completed, one 
member of the team, Yoshiyata Takahashi, while doing library 
research found a neglected paper that was to be very impor-
tant. The paper, from 1917, demonstrated that pineal extracts 
from cows could lighten the color of tadpoles. From the work 
of the Lerner group and that of others it was known that vari-
ous neuroregulators, such as transmitters, could change the 
dispersion of melanin granules. Was the factor in the pineal 
gland a known substance or something new? Lerner and his 
colleagues already knew how to assay for such materials and 
agreed to start a project in which Takahashi would perform 
the bioassays and Lerner would do the extractions.
The project took more than four years (1955–1959), with 
two phases each of about two years, and involved a small 
group, but only Lerner was involved from start to finish. He 
worked every single day. The result was the discovery and 
characterization of melatonin, a new indole, derived from 
serotonin, which is remarkable in its effects on pigmentation. 
The discovery of melatonin reawakened interest in the pine-
al gland, which had been once thought of as the seat of the 
soul. We now know that melatonin is important in the inte-
gration of information related to light and circadian process-
es. It impacts the brain, may be important for some reproduc-
tive processes, and may be relevant to the understanding and 
treatment of phase-shift-related disorders, including some 
forms of depression.
The melatonin team was small but international in ori-
gins, with a broad array of backgrounds and interests. Dr. 
Takahashi was a postdoctoral fellow who had come from 
Tokyo University to Oregon, where he worked with Lerner, 
and he came with him to Yale in 1955. In addition to his 
excellent skills in research work, Dr. Takahashi was deeply 
absorbed in learning the extant literature on pigment biology 
and spent much time in the library (a key to the discovery 
because most people do not go back to read papers from 
1917!). An internist with biochemical training, he returned 
to Japan after two years, having been involved in the early 
isolation and assay processes. Dr. Takahashi became one of 
Japan’s leading experts on the liver and served as chair of the 
Department of Internal Medicine at Gifu University and later 
the president of a major hospital. He is now deceased.
The other critical person present at the start of the project 
was Teh H. Lee. A graduate student in chemical engineering 
at the University of Michigan, Lee was one of 30 gifted young 
people in China selected from 5,000 applicants to obtain 
graduate training in the United States. He started to work 
with Lerner while at Michigan and went with him to Oregon 
and then to Yale. He played a brilliant role in various com-
plex peptide projects, including MSH and ACTH. Lee’s work 
on the melatonin project involved isolation procedures, and 
after a period he returned to the highly important work on 
peptides that was ongoing in the lab at the same time that the 
melatonin project was in full force. Dr. Lee left the lab in the 
mid 1960s and continued research on peptides at a veterans’ 
hospital in Denver, having made extraordinary contributions 
to dermatology. He has remained in the United States.
In 1957, James Case, a gifted resident in dermatology, 
came from Oregon. With a degree in chemical engineering 
and an MS in biochemistry, he was a physician with bio-
chemical experience. Case, who had met Lerner while at 
Oregon, became a major figure in the isolation and structure 
studies. Lerner said of him, “He was tremendous worker who 
could spend night and weekends in the laboratory . . . Jim 
and I worked together hour after hour on the melatonin proj-
ect. Even though it often seemed that we never would accom-
plish the isolation and structural determination of melatonin, 
we finally succeeded.” Following his work at Yale with its 
great success, Case went to the University of Washington, 
where he was very popular (in my recollections, he had a 
natural grace of movement and spirit). Case was appointed 
as an assistant professor and as the first head of the section 
on dermatology at that institution, before his untimely death 
related to an episode of depression.
Another important new member of the lab was M. Ruth 
Wright, a physician from England who worked part-time in 
the lab, which she joined in mid-1956. She was involved in 
and published work on the development of assays as well 
as on the localization of melatonin. She was gracious and 
helpful, and I greatly appreciated her patience in teaching 
me the bioassay methods—although, out of that and similar 
other experiences, later in my career I went to great efforts 
to develop various chemical procedures for neuroregulators. 
She continued in the lab for a few years, later spent some 
time in the Department of Pediatrics at Yale, and regret-
tably passed away at a relatively early age as a result of an 
auto accident.
Wataru Mori began a postdoctoral fellowship with Lerner 
in November 1956. He became quite important in the final 
steps of the melatonin project. Dr. Mori, then and now a 
man of intelligence, elegance, and effectiveness, gracious-
ly responded to my questions about that early phase of the 
work and his interaction with Dr. Lerner. He expressed deep 
respect for the fundamental humanity of Lerner, his fairness, 
and his welcoming attitude and openness to people of other 
cultures, including those with whom the country then had 
recently been at war. The following has been slightly modi-
fied from Dr. Mori’s written reply:
When Dr. Takahashi made up his mind to go back to 
Japan, he had a talk with Dr. Lerner, who wanted to have 
some other person from Japan, but this time not biochemi-
cal in orientation because [Lerner] had a background of 
biochemistry and there were other talented biochemists in 
the laboratory. Therefore, he wanted a morphologist who 
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could use a microscope to watch pigment cells. Takahashi 
wrote this request to his boss in Japan, who recommended 
me since I was working in the Department of Pathology. . . . 
I made movies at Yale of the movement of the pigment cells. 
Very accurate assay was needed. Frogs of the best condi-
tion were selected (shipped each day from Wisconsin) and 
prepared for bioassay. Dr. Lerner was quite busy in clinical 
work during the day. He went home for dinner and came 
back to the laboratory. He worked till late and prepared 
materials for another bioassay for the next day. Our bioas-
say was performed photometrically, using equipment com-
bining a microscope and a photometer. It was used during 
the critical points of the isolation work. The assay required 
“art,” using only the best part of the frog skin, which had to 
be checked through the microscope. I had to decide. Now 
I fully understand the meaning of Dr. Lerner’s request: “We 
need a morphologist now.” . . . James Case was gentle and 
of very nice character and [during that period] did most of 
the work in melatonin isolation. He was loved and respect-
ed by all of the people around.
Dr. Mori later became chair of the Department of Pathology 
at the University of Tokyo, the dean of the university’s medical 
school, and then the president of the university. To Lerner’s 
great pleasure Mori was the first person from Japan to be 
elected to the Institute of Medicine of the National Academy 
of Sciences in the United States. For his multiple extraordi-
nary accomplishments, Dr. Mori has received many hon-
ors in Japan, including being chairman of the Health Care 
Science Institute.
Dr. Lerner often expressed his great pleasure that each of 
these individuals had gotten his start with melatonin!
Memories of a junior and temporary participant in the 
melatonin team
My own contact with Aaron Lerner came as a medical stu-
dent at Yale, taking a junior year in research. I wanted to 
study the neurochemistry of the brain—specifically, to inves-
tigate the ways it might be changed by behavior. At the time 
the Department of Psychiatry at Yale (now a powerhouse 
in biomedical research) had no pH meter, no labs, and no 
money. The chair of biochemistry, who believed it would be 
100 years before one could usefully study the biochemistry 
of the brain, declined to lend Psychiatry a pH meter. He had 
absolute certainty that neurochemistry would not be changed 
by behavior because, as he stated, “Behavior is like the wind, 
biochemistry a locomotive, and the wind does not affect the 
locomotive.” Fortunately, he did tell me that I should talk to 
the new young head of dermatology about medical research. 
Wonderful advice! And, for me, life changing.
I met Aaron in 1957–1958, when the melatonin project 
was in full bloom. He was then in his late 30s. He was a man 
of medium height, thin, with a natural grace in his move-
ments, a wonderful warm smile of good humor, and kind, 
never sarcastic, wit. He always wore a white lab coat and had 
many writing implements, a small flashlight, and, as I remem-
ber, sometimes a small slide rule in his pocket. His group had 
limited lab space, a room smaller than 20 × 20 square feet in 
the basement, with two or three other smaller rooms of about 
10 × 15. The lab was crowded with equipment, neat, and 
functionally organized in a very efficient manner. Aaron radi-
ated joy in the spirit of inquiry; intense, curious, hypothesis 
oriented, he had an ability to draw you into the excitement. 
You could see the dramatic effect of the pineal extracts on 
tadpoles. He was onto something important. The group was 
fired up and shared the excitement. Everyone felt that he or 
she was a vital part of the team. In his memoir of the project, 
Aaron thanks, by name, the dishwasher as well as each of the 
others of us in the lab during that period.
Aaron Lerner was as extraordinary a mentor as he was a 
scientist. The work with him was a key to my approach to 
science and to my decades of research on neuroregulators, 
which later included the first demonstration that the wind 
(behavior) can indeed differentially change the locomotive 
(neurotransmitters). I was fortunate, being the only medical 
student in their small, close-knit laboratory. The lab was quiet 
and intense—not chatty, gossipy, or political, as some are; 
nevertheless, Aaron often invited me to talk with him in his 
office or while he was doing lab work. He graciously spent 
time telling me stories and talking about life and careers in 
medical research. I cherish having had those special chances 
to interact with Professor Lerner and only wish I had taken 
notes! Over five decades he became not only a mentor who 
had profoundly impacted my work but also a great friend and 
really a hybrid of friend and family. My respect for him knew 
no bounds.
Aaron was not afraid of new ideas, new approaches, or 
new technologies and immersed himself in them. Perhaps 
growing out of his sound training with excellent people in 
difficult areas of science, he never seemed fazed by having 
to consider a new facet. His driving force was the intellectual 
problem, rather than knowing a specific method and trying 
to find ways to utilize it. He read widely (all too many schol-
ars don’t) and loved books and good libraries. He was intel-
lectual and enjoyed relating ideas to one another; it was part 
of the secret of his ability to do translational research in such 
a natural manner. He enjoyed talking with others about what 
he was reading. In the days before Current Contents, Aaron 
subscribed to and read Chemical Abstracts—most medical 
researchers did not sit and read Chemical Abstracts for plea-
sure and interest: they found it unbelievably dull.
A key aspect of Aaron’s leadership was his ability to 
bring out the best in each of us. He got the 125% out of 
you that you didn’t know was there; you wanted to get into 
the lab and get results! Each of us had a role. He knew our 
strengths and our interests and how to harness them. My 
project, which worked, was to show that melatonin was 
released and might be a hormone. (Later, with others, I 
found that melatonin is made by humans in the pineal gland 
throughout life, even when it is calcified, and did various 
pharmacological studies including demonstrating that it 
affects sleep.) Aaron had persistence, did not take no for an 
answer, and had the capacity to get everyone involved. He 
persuaded a major processing company to provide bovine 
pineal glands for a project that ended up requiring 250,000 
glands. I remember a shipment of 100,000 that arrived in a 
IN MEMORIAM
2088 Journal of Investigative Dermatology (2007), Volume 127
huge transparent plastic bag. The company had never col-
lected pineal glands before!
Research was a joy to Aaron, which he transmitted to those 
who worked with him. He liked to do research with his own 
two hands. Fortunately he enjoyed lab work, because there 
were no funds for technicians in the lab. He could do every-
thing, including the scut that many lab directors would never 
think of doing themselves. I have a vivid memory of Aaron 
operating a large Craig countercurrent instrument separat-
ing fractions for biological assay. He also enjoyed invent-
ing, exemplified by his development of the Lerner Lab Jack 
for placing equipment at exactly the right height. Aaron was 
good with his hands and said that as a youngster he enjoyed 
repairing things and watching tradespeople, for whom he had 
great respect. He always liked mechanical things that worked 
well and, known for his ability to repair anything, had a very 
impressive and complete workshop at home. When young he 
had worked on cars, but he drove rather nondescript vehicles 
as a faculty member—for his 65th birthday his sons gave him 
a new Corvette!
What made Lerner so effective?
Aside from his skills as a scientist and in motivating people 
and running the lab, Aaron had guts and he wasn’t afraid of a 
fight. The first presentation at Yale of the structure of melato-
nin was to the department of biochemistry. After Aaron’s talk, 
the chair stated in the strongest possible terms that the pro-
posed structure of melatonin had to be wrong—if both active 
groups of the parent molecule, serotonin, were blocked, 
the structure that Aaron had proposed could not be correct. 
Aaron, always soft-spoken, graciously but forcefully stood his 
ground. It was a dramatic moment, but as a medical student 
working with him I was terrified. Aaron was right.
There are also many things I remember about Aaron’s style 
of administration. A well-organized and tireless worker, he 
came in after a swim early each morning, usually before any-
one else, knowing exactly what needed to be done that day. 
He knew how he was going to balance the lab work with his 
clinical and administrative tasks. In five decades, I have never 
known anyone at any institution who could handle those dif-
ferent domains so cleanly and effectively.
Among his administrative tricks was a unique filing sys-
tem: piles of files and papers, high but neat. He knew where 
everything was within a given pile. I often saw that in his 
hands (but unfortunately not in mine today) it was a fast way 
to retrieve things. He had spunk and did not take no for an 
answer in an administrative knockabout. Who else on the 
Yale faculty 50 years ago, having to be in two cities at the 
same time, would have chartered a small private plane and 
then bemusedly explained to Yale administrators why it was 
necessary—and won? Indeed, Aaron was very careful with 
budgets and with expenses, and he was scrupulously honest. 
He called things as he saw them and always pushed Yale to 
expand still further its great research enterprise and needed 
facilities, as well as its need to improve such things as pen-
sions for its nonfaculty employees.
As an administrator, Aaron radiated a love of his depart-
ment. He thought about how to make it better and how to 
help the people in it; he enjoyed and developed people 
regardless of their interests—whether they were slated to go 
into dermatology or psychiatry or become university admin-
istrators. He was especially kind about my interest in psychi-
atry—he pointed out that one could do the same research on 
neurotransmitters in dermatology and have immediate access 
to the tissue. He enjoyed people regardless of their role, rank, 
or background and treated everyone with enormous warmth 
and respect, and they recognized his genuine interest in them 
as well as in their work.
Aaron took the clinical world seriously and esteemed the 
people in it. He was a spectacular clinician at Yale, where 
clinical excellence was a prized value. With his wonderful 
intelligence and memory for detail, Aaron had an ability to 
quickly evaluate clinical problems of great complexity. He 
was known for being able to see a large number of patients 
in any given clinic session but with such interpersonal 
warmth and directness that the patients did not feel rushed 
and loved him. He took residents seriously. Three in particu-
lar stand out in my memory because while young they func-
tioned as faculty and clinical leaders, were involved in excit-
ing research in various areas, and were completely trusted 
by Aaron: Marie-Louise Johnson, MD, PhD, who in addition 
to being a well-regarded dermatologist went on to make 
substantive contributions to the study of the atomic bomb 
survivors and is now a member of the Institute of Medicine; 
Joseph McGuire, MD, who had an outstanding clinical and 
research career at Yale and Stanford; and Irwin Braverman, 
MD, who has had a distinguished academic and clinical 
career at Yale.
The book by Aaron and his first wife, Marguerite, 
Dermatologic Medications, grew out of their joint love for the 
clinical and educational world. It also reflected their style: 
effective, important, and concise. Once, Aaron had an hour 
to give a lecture to the medical students; he completed a 
superb presentation in 20 minutes and stopped. This was the 
only time that happened in my 5 years at Yale. He had that 
same efficiency about time in other presentations, such as site 
visits on grants. Aaron’s widow, Mildred Lerner, has gracious-
ly given me a copy of a 1985 memo in which he instructed 
the members of a team preparing for a visit from the National 
Institutes of Health on the necessity of sticking to the brief 
time allowed for each talk and the importance of absolute 
readability for their slides—“Don’t say ‘please excuse this 
slide’”—completely typical of his approach, which was to 
create optimal efficiency while treating the visitor or the stu-
dent with respect.
Through his administration, research, teaching, and clini-
cal work, Aaron Lerner demonstrated the power of quiet 
charisma. He was a man of absolute grace, who enjoyed 
everyone but handled everything quietly. Almost self-effac-
ing, he never tried to draw attention to himself; he did not 
brag, he did not shout. Yet everyone who worked with him 
knew instinctively not only that Aaron was a person of great 
intelligence and capacity but also that they could trust him 
completely. And they knew that he wanted to help them.
Aaron’s mentorship included interactions about life as well 
as about science, and I was fortunate to receive those lessons 
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through the decades. One lesson was the value of a practi-
cal perspective. At one point, I needed fresh bovine pineal 
glands for an enzyme assay. Aaron sent me to a small kosher 
slaughterhouse in a neighboring town. One of the members 
of the family who owned the place welcomed me graciously. 
He provided the head of a just-sacrificed animal, a large axe, 
and a high solid pedestal. I gave it my best. The head slid off 
the pedestal. Without a word, he took back the axe with one 
hand, picked up the head with the other, and with one pow-
erful, well-aimed swing, split the head, revealing the pineal 
gland. Then he told me that two decades earlier (during the 
depression and before World War II) he had done very well 
in college but had not been accepted into medical school (in 
those days the admitted class in many schools was limited to 
3% to 5% persons of Jewish background) and instead joined 
the family business. My new friend at the slaughterhouse 
warmly wished me well. Aaron and I discussed the experi-
ence, as we also talked at various times about positive and 
negative aspects of redevelopment of New Haven, the open-
ing of opportunity, and civil rights. He had a strong moral 
sense; although nonpartisan in our discussions, he expressed 
strong beliefs in pragmatic politics to achieve good aims, 
and a commitment to justice—or the elimination of injustice 
wherever we could.
I want to mention personal aspects of our relationship 
for which I am deeply thankful. Aaron and Marguerite were 
critical role models; my late wife, Patricia, and I were newly 
married when we met Aaron and Marguerite. Marguerite 
was a gifted clinical dermatologist and also an author of 
children’s books. They were the first couple we knew in 
which both were successful academics. They had four 
sons, of whom they were very proud. They lived simply and 
unpretentiously. We were Californians and they lived in a 
California-style house they had designed themselves. Aaron 
was a great biochemist, but he could also do a splendid 
barbeque. We could sense in the way they interacted with 
each other that they were very happy together. They were 
our models as we developed our lives, in which Pat became 
a faculty member in sociology at Stanford and a pioneer 
in the study of the relationship between social behavior 
and physiology.
Aaron was always a teacher. Our son, Isaac, now execu-
tive director of the Austin Technology Incubator, remem-
bers that when he was a youngster, Aaron visited Palo Alto 
and gave him a slide rule (Aaron loved slide rules!) and 
spent an hour teaching him how to use it. He always asked 
after Isaac.
Aaron was a role model to me through his handling of 
Marguerite’s illness; his thoughtful caring attention was pal-
pable. It was important as I dealt with the brain tumor that Pat 
had for half the 36 years we were married. Aaron and Millie, 
his widow, were together for about 2 decades. Millie had a 
high position in nursing at Yale. Aaron and Millie as a couple 
were again very important role models; their loving and mov-
ing interaction gave a profound sense that one can unexpect-
edly enter a new relationship and the miracle of having had 
two great loves. I have experienced that through my marriage 
to Rosemary Stevens.
I went to New Haven last year to see Aaron. Although ill, he 
was his indomitable self—with his wit and quick understand-
ing, his usual quiet shy smile, his dignity and selflessness, and, 
as always, his intrinsic creativity and infectious pleasure in 
ideas. Aaron Lerner truly was the ideal mentor who became 
a cross between a profound friend and a much-loved family 
member. With his capacity to enjoy the multiple forms of suc-
cess of the people who had worked with him, he expressed his 
pride in the continued excellence of the department and last-
ing love of his chosen field.
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